MedTrace Logo

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

NCT04296786 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-03-05

No results posted yet for this study

Summary

This is a multicenter prospective single arm phase II study. The purpose of this study is to evaluate the safety and efficiency of Sintilimab combined with Chidamide in the treatment of relapsed/refractory cutaneous T-cell lymphoma.

Conditions

  • Cutaneous T-cell Lymphoma

Interventions

DRUG

Sintilimab

200mg intravenously on day 1, every 21 days for 1 cycle, 96 weeks for protocol treatment

DRUG

Chidamide

20mg po per week continuously

Sponsors & Collaborators

  • Peking University Third Hospital

    collaborator OTHER

  • Beijing Longfu Hospital

    collaborator UNKNOWN

  • Dongzhimen Hospital, Beijing

    collaborator OTHER

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2022-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04296786 on ClinicalTrials.gov